Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 488

1.

The Utility of Prostate Specific Antigen Density, Prostate Health Index, and Prostate Health Index Density in Predicting Positive Prostate Biopsy Outcome is Dependent on the Prostate Biopsy Methods.

Lopes Vendrami C, McCarthy RJ, Chatterjee A, Casalino D, Schaeffer EM, Catalona WJ, Miller FH.

Urology. 2019 Jul;129:153-159. doi: 10.1016/j.urology.2019.03.018. Epub 2019 Mar 27.

PMID:
30926382
2.

Genistein treatment duration effects biomarkers of cell motility in human prostate.

Zhang H, Gordon R, Li W, Yang X, Pattanayak A, Fowler G, Zhang L, Catalona WJ, Ding Y, Xu L, Huang X, Jovanovic B, Kelly DL, Jiang H, Bergan R.

PLoS One. 2019 Mar 27;14(3):e0214078. doi: 10.1371/journal.pone.0214078. eCollection 2019.

3.

Approaches to urinary detection of prostate cancer.

Eskra JN, Rabizadeh D, Pavlovich CP, Catalona WJ, Luo J.

Prostate Cancer Prostatic Dis. 2019 Sep;22(3):362-381. doi: 10.1038/s41391-019-0127-4. Epub 2019 Jan 17.

4.

Inflammatory Bowel Disease and the Risk of Prostate Cancer.

Burns JA, Weiner AB, Catalona WJ, Li EV, Schaeffer EM, Hanauer SB, Strong S, Burns J, Hussain MHA, Kundu SD.

Eur Urol. 2019 May;75(5):846-852. doi: 10.1016/j.eururo.2018.11.039. Epub 2018 Dec 4.

PMID:
30528221
5.

Self-reported Black race predicts significant prostate cancer independent of clinical setting and clinical and socioeconomic risk factors.

Nettey OS, Walker AJ, Keeter MK, Singal A, Nugooru A, Martin IK, Ruden M, Gogana P, Dixon MA, Osuma T, Hollowell CMP, Sharifi R, Sekosan M, Yang X, Catalona WJ, Kajdacsy-Balla A, Macias V, Kittles RA, Murphy AB.

Urol Oncol. 2018 Nov;36(11):501.e1-501.e8. doi: 10.1016/j.urolonc.2018.06.011. Epub 2018 Sep 17.

6.

The Influence of Decision Aids on Prostate Cancer Screening Preferences: A Randomized Survey Study.

Weiner AB, Tsai KP, Keeter MK, Victorson DE, Schaeffer EM, Catalona WJ, Kundu SD.

J Urol. 2018 Nov;200(5):1048-1055. doi: 10.1016/j.juro.2018.05.093. Epub 2018 May 29.

7.

Prostate Cancer Screening.

Catalona WJ.

Med Clin North Am. 2018 Mar;102(2):199-214. doi: 10.1016/j.mcna.2017.11.001. Review.

8.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.

J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13. Review.

9.

Reply by the Authors.

Oberlin DT, Catalona WJ, Meeks JJ.

Urology. 2017 Dec;110:267-268. doi: 10.1016/j.urology.2017.08.023. Epub 2017 Aug 25. No abstract available.

10.

A multiparametric approach to improve upon existing prostate cancer screening and biopsy recommendations.

Helfand BT, Conran CA, Xu J, Catalona WJ.

Curr Opin Urol. 2017 Sep;27(5):475-480. doi: 10.1097/MOU.0000000000000418. Review.

11.

Active Surveillance in Younger Men With Prostate Cancer.

Leapman MS, Cowan JE, Nguyen HG, Shinohara KK, Perez N, Cooperberg MR, Catalona WJ, Carroll PR.

J Clin Oncol. 2017 Jun 10;35(17):1898-1904. doi: 10.1200/JCO.2016.68.0058. Epub 2017 Mar 27.

12.

gsSKAT: Rapid gene set analysis and multiple testing correction for rare-variant association studies using weighted linear kernels.

Larson NB, McDonnell S, Cannon Albright L, Teerlink C, Stanford J, Ostrander EA, Isaacs WB, Xu J, Cooney KA, Lange E, Schleutker J, Carpten JD, Powell I, Bailey-Wilson JE, Cussenot O, Cancel-Tassin G, Giles GG, MacInnis RJ, Maier C, Whittemore AS, Hsieh CL, Wiklund F, Catalona WJ, Foulkes W, Mandal D, Eeles R, Kote-Jarai Z, Ackerman MJ, Olson TM, Klein CJ, Thibodeau SN, Schaid DJ.

Genet Epidemiol. 2017 May;41(4):297-308. doi: 10.1002/gepi.22036. Epub 2017 Feb 16. Erratum in: Genet Epidemiol. 2017 Nov;41(7):710.

13.

Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men.

Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, DeKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC.

J Urol. 2017 Feb;197(2S):S200-S207. doi: 10.1016/j.juro.2016.10.073. Epub 2016 Dec 22.

PMID:
28012755
14.

Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer.

Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RHN, Slawin KM, Marks LS, Catalona WJ.

BJU Int. 2017 Jul;120(1):61-68. doi: 10.1111/bju.13676. Epub 2016 Nov 22.

15.

Does prostate volume correlate with vitamin D deficiency among men undergoing prostate biopsy?

Murphy AB, Nyame YA, Batai K, Kalu R, Khan A, Gogana P, Dixon M, Macias V, Kajdacsy-Balla A, Hollowell CM, Catalona WJ, Kittles R.

Prostate Cancer Prostatic Dis. 2017 Mar;20(1):55-60. doi: 10.1038/pcan.2016.41. Epub 2016 Oct 11.

16.

REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants.

Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, Musolf A, Li Q, Holzinger E, Karyadi D, Cannon-Albright LA, Teerlink CC, Stanford JL, Isaacs WB, Xu J, Cooney KA, Lange EM, Schleutker J, Carpten JD, Powell IJ, Cussenot O, Cancel-Tassin G, Giles GG, MacInnis RJ, Maier C, Hsieh CL, Wiklund F, Catalona WJ, Foulkes WD, Mandal D, Eeles RA, Kote-Jarai Z, Bustamante CD, Schaid DJ, Hastie T, Ostrander EA, Bailey-Wilson JE, Radivojac P, Thibodeau SN, Whittemore AS, Sieh W.

Am J Hum Genet. 2016 Oct 6;99(4):877-885. doi: 10.1016/j.ajhg.2016.08.016. Epub 2016 Sep 22.

17.

Reply to E. Roca et al.

Nyame YA, Murphy AB, Jordan G, Gogana P, Hollowell CMP, Catalona WJ, Kittles R.

J Clin Oncol. 2016 Oct 20;34(30):3710-3711. doi: 10.1200/JCO.2016.68.9299. No abstract available.

PMID:
27458284
18.

Post hoc Analysis for Detecting Individual Rare Variant Risk Associations Using Probit Regression Bayesian Variable Selection Methods in Case-Control Sequencing Studies.

Larson NB, McDonnell S, Albright LC, Teerlink C, Stanford J, Ostrander EA, Isaacs WB, Xu J, Cooney KA, Lange E, Schleutker J, Carpten JD, Powell I, Bailey-Wilson J, Cussenot O, Cancel-Tassin G, Giles G, MacInnis R, Maier C, Whittemore AS, Hsieh CL, Wiklund F, Catalona WJ, Foulkes W, Mandal D, Eeles R, Kote-Jarai Z, Ackerman MJ, Olson TM, Klein CJ, Thibodeau SN, Schaid DJ.

Genet Epidemiol. 2016 Sep;40(6):461-9. doi: 10.1002/gepi.21983. Epub 2016 Jun 17. Erratum in: Genet Epidemiol. 2017 Nov;41(7):710.

19.

Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21.

Teerlink CC, Leongamornlert D, Dadaev T, Thomas A, Farnham J, Stephenson RA, Riska S, McDonnell SK, Schaid DJ, Catalona WJ, Zheng SL, Cooney KA, Ray AM, Zuhlke KA, Lange EM, Giles GG, Southey MC, Fitzgerald LM, Rinckleb A, Luedeke M, Maier C, Stanford JL, Ostrander EA, Kaikkonen EM, Sipeky C, Tammela T, Schleutker J, Wiley KE, Isaacs SD, Walsh PC, Isaacs WB, Xu J, Cancel-Tassin G, Cussenot O, Mandal D, Laurie C, Laurie C; PRACTICAL consortium; International Consortium for Prostate Cancer Genetics, Thibodeau SN, Eeles RA, Kote-Jarai Z, Cannon-Albright L.

Hum Genet. 2016 Aug;135(8):923-38. doi: 10.1007/s00439-016-1690-6. Epub 2016 Jun 4.

20.

NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.

Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP 3rd, Kawachi MH, Kim S, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Moses KA, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenkle P, Vickers AJ, Wake R, Shead DA, Freedman-Cass DA.

J Natl Compr Canc Netw. 2016 May;14(5):509-19.

PMID:
27160230
21.

Diagnostic Value of Guided Biopsies: Fusion and Cognitive-registration Magnetic Resonance Imaging Versus Conventional Ultrasound Biopsy of the Prostate.

Oberlin DT, Casalino DD, Miller FH, Matulewicz RS, Perry KT, Nadler RB, Kundu S, Catalona WJ, Meeks JJ.

Urology. 2016 Jun;92:75-9. doi: 10.1016/j.urology.2016.02.041. Epub 2016 Mar 7.

22.

Mutational Landscape of Aggressive Prostate Tumors in African American Men.

Lindquist KJ, Paris PL, Hoffmann TJ, Cardin NJ, Kazma R, Mefford JA, Simko JP, Ngo V, Chen Y, Levin AM, Chitale D, Helfand BT, Catalona WJ, Rybicki BA, Witte JS.

Cancer Res. 2016 Apr 1;76(7):1860-8. doi: 10.1158/0008-5472.CAN-15-1787. Epub 2016 Feb 26.

23.

Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy.

Nyame YA, Murphy AB, Bowen DK, Jordan G, Batai K, Dixon M, Hollowell CM, Kielb S, Meeks JJ, Gann PH, Macias V, Kajdacsy-Balla A, Catalona WJ, Kittles R.

J Clin Oncol. 2016 Apr 20;34(12):1345-9. doi: 10.1200/JCO.2015.65.1463. Epub 2016 Feb 22.

24.

Insertion of an SVA-E retrotransposon into the CASP8 gene is associated with protection against prostate cancer.

Stacey SN, Kehr B, Gudmundsson J, Zink F, Jonasdottir A, Gudjonsson SA, Sigurdsson A, Halldorsson BV, Agnarsson BA, Benediktsdottir KR, Aben KK, Vermeulen SH, Cremers RG, Panadero A, Helfand BT, Cooper PR, Donovan JL, Hamdy FC, Jinga V, Okamoto I, Jonasson JG, Tryggvadottir L, Johannsdottir H, Kristinsdottir AM, Masson G, Magnusson OT, Iordache PD, Helgason A, Helgason H, Sulem P, Gudbjartsson DF, Kong A, Jonsson E, Barkardottir RB, Einarsson GV, Rafnar T, Thorsteinsdottir U, Mates IN, Neal DE, Catalona WJ, Mayordomo JI, Kiemeney LA, Thorleifsson G, Stefansson K.

Hum Mol Genet. 2016 Mar 1;25(5):1008-18. doi: 10.1093/hmg/ddv622. Epub 2016 Jan 5.

25.

NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015.

Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP 3rd, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenke P, Vickers AJ, Wake R, Shead DA, Freedman-Cass D.

J Natl Compr Canc Netw. 2015 Dec;13(12):1534-61.

PMID:
26656522
26.

The Prostate Health Index: Its Utility in Prostate Cancer Detection.

Lepor A, Catalona WJ, Loeb S.

Urol Clin North Am. 2016 Feb;43(1):1-6. doi: 10.1016/j.ucl.2015.08.001. Review.

27.

Associations Between iCOGS Single Nucleotide Polymorphisms and Upgrading in Both Surgical and Active Surveillance Cohorts of Men with Prostate Cancer.

Kearns JT, Lapin B, Wang E, Roehl KA, Cooper P, Catalona WJ, Helfand BT.

Eur Urol. 2016 Feb;69(2):223-8. doi: 10.1016/j.eururo.2015.09.004. Epub 2015 Sep 26.

28.

Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases.

Helfand BT, Roehl KA, Cooper PR, McGuire BB, Fitzgerald LM, Cancel-Tassin G, Cornu JN, Bauer S, Van Blarigan EL, Chen X, Duggan D, Ostrander EA, Gwo-Shu M, Zhang ZF, Chang SC, Jeong S, Fontham ET, Smith G, Mohler JL, Berndt SI, McDonnell SK, Kittles R, Rybicki BA, Freedman M, Kantoff PW, Pomerantz M, Breyer JP, Smith JR, Rebbeck TR, Mercola D, Isaacs WB, Wiklund F, Cussenot O, Thibodeau SN, Schaid DJ, Cannon-Albright L, Cooney KA, Chanock SJ, Stanford JL, Chan JM, Witte J, Xu J, Bensen JT, Taylor JA, Catalona WJ.

Hum Genet. 2015 Apr;134(4):439-50. doi: 10.1007/s00439-015-1534-9. Epub 2015 Feb 26.

29.

The prostate health index selectively identifies clinically significant prostate cancer.

Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, Partin AW, Klee GG, Slawin KM, Marks LS, van Schaik RH, Chan DW, Sokoll LJ, Cruz AB, Mizrahi IA, Catalona WJ.

J Urol. 2015 Apr;193(4):1163-9. doi: 10.1016/j.juro.2014.10.121. Epub 2014 Nov 15.

30.

A genetic-based approach to personalized prostate cancer screening and treatment.

Helfand BT, Catalona WJ, Xu J.

Curr Opin Urol. 2015 Jan;25(1):53-8. doi: 10.1097/MOU.0000000000000130. Review.

31.

History of the discovery and clinical translation of prostate-specific antigen.

Catalona WJ.

Asian J Urol. 2014 Oct;1(1):12-14. doi: 10.1016/j.ajur.2014.09.008. Epub 2015 Apr 16. No abstract available.

32.

Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines.

Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP 3rd, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shanefelt TM, Vickers AJ, Wake R, Shead DA, Ho M; National comprehensive cancer network.

J Natl Compr Canc Netw. 2014 Sep;12(9):1211-9; quiz 1219.

PMID:
25190691
33.

A rare 8q24 single nucleotide polymorphism (SNP) predisposes North American men to prostate cancer and possibly more aggressive disease.

Grin B, Loeb S, Roehl K, Cooper PR, Catalona WJ, Helfand BT.

BJU Int. 2015 Jan;115(1):101-5. doi: 10.1111/bju.12847. Epub 2014 Sep 25.

34.

Vitamin D deficiency predicts prostate biopsy outcomes.

Murphy AB, Nyame Y, Martin IK, Catalona WJ, Hollowell CM, Nadler RB, Kozlowski JM, Perry KT, Kajdacsy-Balla A, Kittles R.

Clin Cancer Res. 2014 May 1;20(9):2289-99. doi: 10.1158/1078-0432.CCR-13-3085.

35.

The epidemiology and clinical implications of genetic variation in prostate cancer.

Helfand BT, Catalona WJ.

Urol Clin North Am. 2014 May;41(2):277-97. doi: 10.1016/j.ucl.2014.01.001. Epub 2014 Feb 28. Review.

PMID:
24725490
36.

Genetically adjusted prostate-specific antigen values may prevent delayed biopsies in African-American men.

Donin NM, Loeb S, Cooper PR, Roehl KA, Baumann NA, Catalona WJ, Helfand BT.

BJU Int. 2014 Dec;114(6b):E50-E55. doi: 10.1111/bju.12647. Epub 2014 Jul 15.

37.
38.

The Prostate Health Index: a new test for the detection of prostate cancer.

Loeb S, Catalona WJ.

Ther Adv Urol. 2014 Apr;6(2):74-7. doi: 10.1177/1756287213513488. Review.

39.

PSA screening in men newly diagnosed with colorectal cancer: each according to his group's means?

Davis BJ, Pisansky TM, Catalona WJ.

Oncology (Williston Park). 2013 Oct;27(10):1038, 1040. No abstract available.

40.

Prostate cancer risk alleles are associated with prostate cancer volume and prostate size.

Reinhardt D, Helfand BT, Cooper PR, Roehl KA, Catalona WJ, Loeb S.

J Urol. 2014 Jun;191(6):1733-6. doi: 10.1016/j.juro.2013.12.030. Epub 2013 Dec 15.

41.

The Melbourne Consensus Statement on the early detection of prostate cancer.

Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wootten A, Walsh PC, Costello AJ.

BJU Int. 2014 Feb;113(2):186-8. doi: 10.1111/bju.12556. Review.

42.

Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease.

Teerlink CC, Thibodeau SN, McDonnell SK, Schaid DJ, Rinckleb A, Maier C, Vogel W, Cancel-Tassin G, Egrot C, Cussenot O, Foulkes WD, Giles GG, Hopper JL, Severi G, Eeles R, Easton D, Kote-Jarai Z, Guy M, Cooney KA, Ray AM, Zuhlke KA, Lange EM, Fitzgerald LM, Stanford JL, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Isaacs WB, Wahlfors T, Tammela T, Schleutker J, Wiklund F, Grönberg H, Emanuelsson M, Carpten J, Bailey-Wilson J, Whittemore AS, Oakley-Girvan I, Hsieh CL, Catalona WJ, Zheng SL, Jin G, Lu L, Xu J; International Consortium for Prostate Cancer Genetics, Camp NJ, Cannon-Albright LA.

Hum Genet. 2014 Mar;133(3):347-56. doi: 10.1007/s00439-013-1384-2. Epub 2013 Oct 26.

43.

Editorial comment.

Catalona WJ.

Urology. 2013 Dec;82(6):1217-8. doi: 10.1016/j.urology.2013.06.075. Epub 2013 Oct 19. No abstract available.

PMID:
24149108
44.

PSA enzymatic activity: a new biomarker for assessing prostate cancer aggressiveness.

Ahrens MJ, Bertin PA, Vonesh EF, Meade TJ, Catalona WJ, Georganopoulou D.

Prostate. 2013 Dec;73(16):1731-7. doi: 10.1002/pros.22714. Epub 2013 Aug 9.

PMID:
23934862
45.

Re: Early detection of prostate cancer: AUA guideline: H. B. Carter, P. C. Albertsen, M. J. Barry, R. Etzioni, S. J. Freedland, K. L. Greene, L. Holmberg, P. Kantoff, B. R. Konety, M. H. Murad, D. F. Penson and A. L. Zietman J Urol 2013; 190: 419-426.

Moul JW, Walsh PC, Rendell MS, Lynch HT, Leslie SW, Kosoko-Lasaki O, Fitzgibbons WP, Powell I, D'Amico AV, Catalona WJ.

J Urol. 2013 Sep;190(3):1134-7. doi: 10.1016/j.juro.2013.07.002. Epub 2013 Jul 17. No abstract available.

PMID:
23871525
46.

Prostate cancer: the growing evidence supporting mid-life PSA testing.

Reinhardt D, Catalona WJ.

Nat Rev Urol. 2013 Aug;10(8):436-8. doi: 10.1038/nrurol.2013.144. Epub 2013 Jul 2. No abstract available.

PMID:
23817409
47.

Suprapubic tube after radical prostatectomy.

Prasad SM, Smith ND, Catalona WJ, Sammon J, Menon M.

J Urol. 2013 Jun;189(6):2028-30. doi: 10.1016/j.juro.2013.03.031. Epub 2013 Mar 15. No abstract available.

PMID:
23500034
48.

Personalized prostate specific antigen testing using genetic variants may reduce unnecessary prostate biopsies.

Helfand BT, Loeb S, Hu Q, Cooper PR, Roehl KA, McGuire BB, Baumann NA, Catalona WJ.

J Urol. 2013 May;189(5):1697-701. doi: 10.1016/j.juro.2012.12.023. Epub 2013 Feb 27.

49.

Words of wisdom. Re: Quality-of-life effects of prostate-specific antigen screening.

Catalona WJ.

Eur Urol. 2013 Jan;63(1):180. doi: 10.1016/j.eururo.2012.10.030. No abstract available.

PMID:
23218492
50.

Supplemental Content

Loading ...
Support Center